ArticleInternal medicine (Tokyo, Japan)2021
Reply to "Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?"
Hiroaki Matsuura, Keiichi Fujiwara, Hiroki Omori, Kiriko Onishi, Tadahiro Kuribayashi, Sho Mitsumune, Yuki Takigawa, Kenichiro Kudo, Akiko Sato, Ken Sato and 1 more
Open access · diamondAbstract readLetterComment
In one paragraphArticle in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors at 2 institutions in 1 country.
Hiroaki MatsuuraDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Keiichi FujiwaraDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Hiroki OmoriDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Kiriko OnishiDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Tadahiro KuribayashiDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Sho MitsumuneDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Yuki TakigawaDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Kenichiro KudoDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Akiko SatoDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Ken SatoDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
Takuo ShibayamaDepartment of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
National Hospital Organization · JPOkayama Medical Center · JP
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedAspergillosis, Allergic BronchopulmonaryHumansAntibodies, Monoclonal, Humanizedbenralizumaballergic bronchopulmonary aspergillosisbenralizumabbronchial asthmatriazole antifungal
Identifiers
PMID33583909
PMCPMC8381187
OpenAlexW3131349333
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390